APCCC 2024: How to Treat Men with Aggressive Variant or Neuroendocrine Prostate Cancer
APCCC 2024, Aggressive Variant Prostate Cancer, Neuroendocrine Prostate Cancer, Lurbinectedin, CHAMP trial, valemetostat, Tarlatamab (AMG-757), Cisplatin, etoposide, Carboplatin, Docetaxel, Cabazitaxel, Cisplatin/etoposide, Carboplatin/etoposide, Docetaxel/carboplatin, Cabazitaxel/carboplatin, CXCR2 (C-X-C Motif Chemokine Receptor 2), SYNERGY-201 trial, niraparib plus cetrelimab, delta-like ligand 3 (DLL3), Bispecific T-cell Engager (BiTE®) therapy.